Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
PART B OF LBL-047 PHASE I STUDY COMPLETES FIRST DOSING OF A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS; NOVEL BDCA2/TACI DUAL-TARGETING DESIGN ENTERS CLINICAL EVALUATION IN PATIENTS

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that, the first patient with systemic lupus erythematosus ("**SLE**") has been successfully dosed in part B of the Phase I clinical study (LBL-047-CN001) of the Company's self-developed LBL-047, referred to as "DNTH212" outside Greater China, a novel bispecific fusion protein targeting blood dendritic cell antigen 2 ("**BDCA2**") and transmembrane activator and CAML interactor ("**TACI**"). This marks the first administration of LBL-047 to patients with an autoimmune disease. The molecule is designed to target two clinically validated pathogenic pathways involving innate and adaptive immunity, and LBL-047, featuring this differentiated and complementary dual-targeting design, has now been administered to the patient for the first time.

Part B of the LBL-047-CN001 study is designed primarily to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic ("**PK/PD**") profiles and preliminary clinical efficacy of LBL-047 in patients with SLE. Professors Ye Shuang (葉霜) and Chen Sheng (陳盛) of Renji Hospital, Shanghai Jiao Tong University School of Medicine (上海交通大學醫學院附屬仁濟醫院), serve as the principal investigators for Part B. Part A of the study is ongoing at Shanghai Public Health Clinical Center (上海市公共衛生臨床中心), with Professor Meng Xianmin (孟現民) serving as the principal investigator. Safety and pharmacokinetic data accumulated in healthy volunteers in Part A supported the progression of the study to the SLE patient cohort in accordance with the study protocol.

ABOUT SLE

SLE is a heterogeneous systemic autoimmune disease characterized by a relapsing-remitting course. The market for SLE treatment continues to grow in China and the United States. Approximately 107,000 and 34,000 new patients with SLE are reported each year in China and the United States, respectively, while approximately 600,000 and 180,000 patients, respectively, receive ongoing treatment annually. Owing to the complex pathogenesis and substantial heterogeneity of SLE, the relative contributions of pathogenic pathways involving interferons, B cells and plasma cells vary among patients. Existing monoclonal antibody therapies may benefit only certain patient populations, while long-term use of conventional corticosteroids and broad-spectrum immunosuppressants carries risks including infection and osteoporosis. Patients with refractory SLE may continue to experience active disease and progressive organ damage despite standard treatments, highlighting significant unmet medical needs.

ABOUT LBL-047

LBL-047 is a novel bispecific fusion protein comprising a humanized anti-BDCA2 antibody and an engineered TACI ectodomain. It is designed to selectively deplete plasmacytoid dendritic cells ("**pDCs**") to reduce the production of type I interferons ("**IFN-I**"), while simultaneously inhibiting B-cell activating factor ("**BAFF**") and a proliferation-inducing ligand ("**APRIL**") signaling pathways to suppress B-cell activation, differentiation and antibody production. By addressing two key drivers of aberrant immune responses, LBL-047 has the potential to achieve broader and more potent immunomodulation in autoimmune diseases where B cells and/or pDCs play critical roles. In addition, Fc engineering is designed to extend the half-life of LBL-047, potentially reducing dosing frequency and improving patient adherence.

On October 16, 2025, the Company entered into an exclusive global partnership with Dianthus Therapeutics ("**Dianthus**", NASDAQ: DNTH), a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases, with an aggregate potential transaction value of up to US$1 billion. Under the agreement, the Company granted Dianthus exclusive rights to research, develop, manufacture and commercialize LBL-047 outside Greater China, where the candidate is being developed as DNTH212. The parties are working jointly to advance its global clinical development and realize its clinical and commercial potential.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-047, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, October 30, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.